TLDR:
- CAPR fell 12.98% as FDA panel timing moved into focus.
- FDA will review Deramiocel’s DMD application on July 29.
- Capricor says trial data supports skeletal and cardiac benefits.
- DMD remains a severe rare disease with limited treatment options.
- Deramiocel holds several key rare disease regulatory designations.
Capricor Therapeutics, Inc. stock fell 12.98% to $26.45 as traders reacted to a key FDA review update. The company now faces a July 29 advisory panel meeting for Deramiocel. The review places its Duchenne muscular dystrophy program under fresh market focus.
Capricor Therapeutics, Inc., CAPR
FDA Panel Puts Deramiocel In Focus
Capricor said the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee plans to discuss Deramiocel. The meeting will review the company’s Biologics License Application for Duchenne muscular dystrophy. The session will also stream live for public access.
Deramiocel remains an investigational cell therapy for DMD. Capricor submitted the application with data from several clinical studies. These include the Phase 2 HOPE-2 trial and long-term HOPE-2-OLE results.
The company also cited positive Phase 3 HOPE-3 data. That study met its primary endpoint using PUL v2.0. It also reached the key cardiac endpoint based on left ventricular ejection fraction.
CAPR Stock Drops After Review Update
CAPR opened under pressure and moved sharply lower during early trading. The stock later stabilized between $26.40 and $26.60.The decline still reflected a strong reaction to the regulatory timeline.
The July meeting adds a clear date to Capricor’s review process. Market attention now shifts toward the panel discussion and FDA feedback. The outcome may shape expectations for Deramiocel’s approval path.
Capricor said it will support the agency’s review ahead of the meeting. Chief Executive Linda Marbán said the company sees strong evidence across the Deramiocel program. She also said Capricor remains focused on the needs of DMD patients.
DMD Background And Treatment Need
Duchenne muscular dystrophy is a severe genetic disorder. It causes progressive muscle degeneration across skeletal, respiratory, and cardiac muscles. The disease mainly affects boys and has no cure.
DMD comes from the absence of functional dystrophin. This protein helps support normal muscle cell structure. Without it, patients lose muscle function over time.
Heart muscle deterioration can lead to cardiomyopathy and heart failure. Capricor said DMD affects about 15,000 people in the United States. Current treatment choices remain limited, which keeps demand high for new therapies.
Deramiocel Designations Support Review
Deramiocel, also known as CAP-1002, uses allogeneic cardiosphere-derived cells. These cardiac cells have shown immunomodulatory and anti-fibrotic activity in studies. Capricor aims to preserve skeletal and cardiac muscle function in DMD.
The cells secrete extracellular vesicles called exosomes. These vesicles target macrophages and help shift them toward a healing profile. Capricor said CDCs have appeared in more than 250 peer-reviewed publications.
Deramiocel has received Orphan Drug Designation from the FDA and EMA. It also holds RMAT designation in the United States. FDA granted Rare Pediatric Disease Designation, which may support a priority review voucher.
Capricor’s Broader Rare Disease Pipeline
Capricor focuses on cell and exosome-based therapies for rare diseases. Deramiocel remains its lead product candidate in late-stage development. The program targets a disease with major cardiac and skeletal muscle burden.
The company also develops its StealthX exosome platform. This platform targets delivery of oligonucleotides, proteins, and small-molecule therapeutics. Capricor uses the platform across several disease areas.
The FDA advisory meeting now becomes the next major milestone for CAPR stock. The company must present its clinical case before outside experts. The July review will test Deramiocel’s outlook and Capricor’s rare disease strategy.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
